Send the following on WhatsApp
Continue to Chat信達生物宣佈mazdutide (IBI362)在中國2型糖尿病受試者中的III期臨床研究(DREAMS-1)完成首例受試者給藥 https://geneonline.news/%e4%bf%a1%e9%81%94%e7%94%9f%e7%89%a9%e5%ae%a3%e4%bd%88mazdutide-ibi362%e5%9c%a8%e4%b8%ad%e5%9c%8b2%e5%9e%8b%e7%b3%96%e5%b0%bf%e7%97%85%e5%8f%97%e8%a9%a6%e8%80%85%e4%b8%ad%e7%9a%84iii%e6%9c%9f/